Cargando…

Peripheral Glycolysis in Neurodegenerative Diseases

Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Simon M., Burgess, Toby, Lee, James, Blackburn, Daniel J., Allen, Scott P., Mortiboys, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727792/
https://www.ncbi.nlm.nih.gov/pubmed/33255513
http://dx.doi.org/10.3390/ijms21238924
_version_ 1783621130353901568
author Bell, Simon M.
Burgess, Toby
Lee, James
Blackburn, Daniel J.
Allen, Scott P.
Mortiboys, Heather
author_facet Bell, Simon M.
Burgess, Toby
Lee, James
Blackburn, Daniel J.
Allen, Scott P.
Mortiboys, Heather
author_sort Bell, Simon M.
collection PubMed
description Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous system and peripheral cells. Glycolysis is the conversion of glucose to pyruvate or lactate which results in the generation of ATP and has been shown to be abnormal in peripheral cells in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Changes to the glycolytic pathway are seen early in neurodegenerative disease and highlight how in multiple neurodegenerative conditions pathology is not always confined to the nervous system. In this paper, we review the abnormalities described in glycolysis in the three most common neurodegenerative diseases. We show that in all three diseases glycolytic changes are seen in fibroblasts, and red blood cells, and that liver, kidney, muscle and white blood cells have abnormal glycolysis in certain diseases. We highlight there is potential for peripheral glycolysis to be developed into multiple types of disease biomarker, but large-scale bio sampling and deciphering how glycolysis is inherently altered in neurodegenerative disease in multiple patients’ needs to be accomplished first to meet this aim.
format Online
Article
Text
id pubmed-7727792
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77277922020-12-11 Peripheral Glycolysis in Neurodegenerative Diseases Bell, Simon M. Burgess, Toby Lee, James Blackburn, Daniel J. Allen, Scott P. Mortiboys, Heather Int J Mol Sci Review Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous system and peripheral cells. Glycolysis is the conversion of glucose to pyruvate or lactate which results in the generation of ATP and has been shown to be abnormal in peripheral cells in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Changes to the glycolytic pathway are seen early in neurodegenerative disease and highlight how in multiple neurodegenerative conditions pathology is not always confined to the nervous system. In this paper, we review the abnormalities described in glycolysis in the three most common neurodegenerative diseases. We show that in all three diseases glycolytic changes are seen in fibroblasts, and red blood cells, and that liver, kidney, muscle and white blood cells have abnormal glycolysis in certain diseases. We highlight there is potential for peripheral glycolysis to be developed into multiple types of disease biomarker, but large-scale bio sampling and deciphering how glycolysis is inherently altered in neurodegenerative disease in multiple patients’ needs to be accomplished first to meet this aim. MDPI 2020-11-24 /pmc/articles/PMC7727792/ /pubmed/33255513 http://dx.doi.org/10.3390/ijms21238924 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bell, Simon M.
Burgess, Toby
Lee, James
Blackburn, Daniel J.
Allen, Scott P.
Mortiboys, Heather
Peripheral Glycolysis in Neurodegenerative Diseases
title Peripheral Glycolysis in Neurodegenerative Diseases
title_full Peripheral Glycolysis in Neurodegenerative Diseases
title_fullStr Peripheral Glycolysis in Neurodegenerative Diseases
title_full_unstemmed Peripheral Glycolysis in Neurodegenerative Diseases
title_short Peripheral Glycolysis in Neurodegenerative Diseases
title_sort peripheral glycolysis in neurodegenerative diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727792/
https://www.ncbi.nlm.nih.gov/pubmed/33255513
http://dx.doi.org/10.3390/ijms21238924
work_keys_str_mv AT bellsimonm peripheralglycolysisinneurodegenerativediseases
AT burgesstoby peripheralglycolysisinneurodegenerativediseases
AT leejames peripheralglycolysisinneurodegenerativediseases
AT blackburndanielj peripheralglycolysisinneurodegenerativediseases
AT allenscottp peripheralglycolysisinneurodegenerativediseases
AT mortiboysheather peripheralglycolysisinneurodegenerativediseases